Study of carrilizumab combined with cisplatin and fluorouracil in advanced esophageal cancer
Objective This study was aimed to investigate the effect of carrilizumab combined with cisplatin and fluorouracil on patients with advanced esophageal cancer.Methods The clinical data of 98 patients with advanced esophageal cancer admitted to the Department of Oncology and Hematology and Thoracic Surgery of Wuhu First People's Hospital from January 2019 to October 2022 were retrospectively analyzed.According to different treatment regimens,they were divided into study group(carrilizumab+cispl-atin+fluorouracil)and control group(cisplatin+fluorouracil),with 49 cases in each group.After 2 cycles of treatment,the anti-tumor effect,the levels of tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCCA),cytokeratin 19 frag-ment antigen(CYFRA21-1)],T lymphocyte subsets[the proportion of Th1,Th2,Treg,Th17 cells and the proportion of CD4+and CD8+],drug safety and survival within 1 year of treatment were compared.Results The objective response rate and clinical control rate of the study group were higher than those of the control group(P＜0.05).Af-ter treatment,CEA,SCCA,and CYFRA21-1 in the two groups were lower than those before treatment(P＜0.05).The differences between CEA,SCCA,and CYFRA21-1 in the study group before and after treatment were higher than those before treatment(P＜0.05).The Th1/Th2 and Th17/Treg after treatment in the study group were lower than those before treatment.The CD4+/CD8+were higher than those before treatment(P＜0.05).The Th1/Th2 and Th17/Treg after treatment in the control group were higher than those before treatment.The CD4+/CD8+were lower than those before treatment(P＜0.05).The 1-year overall survival rate of the study group was better than that of the control group(P＜0.05).Conclusion Carrilizumab combined with cisplatin and fluorouracil can enhance the short-term anti-tu-mor effect in patients with advanced esophageal cancer,improve the immune function of patients,and prolong the short-term survival rate of patients with good safety.
NETL
NSTL
万方数据
